Cagrilintide Side Effects

The short version

If you search “cagrilintide side effects,” you’ll find confident lists: nausea, constipation, injection-site reactions, occasional vomiting. Those aren’t wrong. But almost every one of them carries an asterisk that most pages quietly drop — the bulk of cagrilintide’s human safety data was generated inside CagriSema, the combination where cagrilintide is dosed together with the GLP-1 drug semaglutide. In that setting, a participant’s nausea could be coming from the amylin analog, from the GLP-1, or from both at once. There’s no clean way to assign blame.

That single fact reshapes how you should read everything else here. Cagrilintide is not a finished, approved medicine with an FDA label that catalogues its risks. It’s an investigational compound whose most-cited safety numbers are really two-drug numbers. This page walks through what’s actually known, where the confounding lives, and why “it has fewer side effects” is a claim that needs a footnote.

Note: This is educational information, not medical advice. Cagrilintide is investigational. Nothing here is a protocol, a dosing recommendation, or a suggestion to use cagrilintide outside a clinical trial or an approved future product.

Why the side-effect data is confounded

Cagrilintide is a long-acting analog of amylin, a hormone your pancreas releases alongside insulin after a meal. Amylin signals the brain to feel full, slows gastric emptying so food moves through the stomach more gradually, and suppresses glucagon release. Engineered to last about a week per injection, cagrilintide produces sustained amylin-receptor activation — and the predictable consequence of slowing the gut is gastrointestinal side effects.

So far so simple. The complication is the development strategy. Novo Nordisk’s flagship program pairs cagrilintide with semaglutide because the combination outperforms either drug alone. The large Phase 3 evidence base — the REDEFINE trials — therefore mostly measures the pair. Phase 3 CagriSema reported about 22.7% weight loss at 68 weeks when paired with semaglutide, and that’s the figure that gets quoted everywhere, including in side-effect discussions.

Here’s the problem in plain terms: nausea is the single most common adverse event for both amylin analogs and GLP-1 drugs. When a CagriSema participant reports nausea, you cannot tell from the data alone whether the amylin half, the GLP-1 half, or the interaction caused it. The same goes for constipation, diarrhea, and reduced appetite. The combination’s side-effect table is genuine — but it is not a cagrilintide side-effect table. It’s a CagriSema one.

This is the core thing to take away: a “cagrilintide side effect” you read online is, more often than not, a CagriSema side effect. Whenever you see a percentage, the first question is “monotherapy or combination?” — because the answer changes what the number means.

What the standalone (monotherapy) data shows

There is standalone human data, it’s just smaller and older. The Phase 2 dose-finding work and the cagrilintide-alone arm of REDEFINE give the cleanest available look at the molecule by itself.

From that monotherapy data, a recognizable amylin-class signature emerges:

• Gastrointestinal effects dominate. In a Phase 2 trial at 4.5 mg/week, nausea occurred in about 47% of participants, constipation in 21%, and vomiting in 8%, with most events mild to moderate and improving as the dose stabilized. Across trials, nausea rates ranged from roughly 20% to 47% depending on dose.
• Injection-site reactions are unusually prominent. This is where the amylin class diverges from GLP-1 drugs. Injection-site reactions occurred at rates dramatically higher than placebo in the same Phase 2 work — redness, soreness, swelling at the injection point. Amylin-class peptides are also handling-sensitive and prone to clumping, which is part of why local reactions feature more here than with semaglutide.
• The “gentler nausea” claim is real but partial. Phase 3 data suggests cagrilintide may have lower rates of nausea and vomiting than GLP-1 therapies like semaglutide, though GI effects still occur and are typically mild to moderate. That’s a meaningful difference — it’s why cagrilintide is studied as an option for people who don’t tolerate GLP-1 drugs well — but it describes monotherapy. Combine it with semaglutide and you reintroduce the GLP-1 GI burden on top.

So the honest monotherapy summary is: meaningfully nauseating but perhaps less so than a GLP-1; notably more likely to irritate the injection site; mostly mild, dose-dependent, and front-loaded into the early weeks.

The amylin mechanism explains the pattern

The side-effect profile isn’t random — it tracks the biology. Cagrilintide primarily activates amylin receptors — the AMY1, AMY2, and AMY3 complexes — along with calcitonin receptors, a different mechanism from GLP-1 receptor agonists. Because amylin’s normal job includes slowing gastric emptying, an engineered version that stays active for a week produces a stronger, longer version of that effect — hence the nausea and constipation. These GI effects are expected, because amylin analogs naturally delay food movement through the stomach.

This is also why dose escalation matters so much for tolerability: easing the receptor into sustained activation gives the gut time to adapt, which is why trials titrate upward rather than starting at the top dose. (How that titration is decided is a clinical question covered on the cagrilintide dosage page — and it is a decision for a prescriber, not a number to copy off a website.)

Less common and serious considerations

Beyond the routine GI and injection-site effects, a few items warrant naming honestly:

• Pancreatitis (rare). Inflammation of the pancreas has been flagged as a rare concern across amylin- and satiety-based therapies; warning signs include severe abdominal pain radiating to the back with nausea and vomiting. It’s uncommon, but it’s the kind of event that means stop and seek care, not wait and see.
• Gallbladder issues. Rapid weight loss of any cause raises gallstone risk, so any drug producing large, fast losses inherits that association.
• Cardiovascular and long-term data still maturing. A 2024 analysis found no clinically relevant QTc prolongation, but the REDEFINE 3 cardiovascular outcomes trial (~7,000 participants) is ongoing and has not yet reported, and multi-year outcomes data is still maturing. Absence of a signal so far is reassuring but not the same as a completed long-term safety record.

Because cagrilintide isn’t approved, none of this is consolidated into an FDA-reviewed label. With semaglutide you can read an official adverse-reactions section; with cagrilintide you’re piecing together trial publications. That gap is itself a safety-relevant fact.

The gray-market problem stacks on top

Everything above assumes pharmaceutical-grade cagrilintide given in a monitored trial. That is not how most people outside a study would encounter it. As of June 2026, standalone cagrilintide is investigational with no FDA approval, and the CagriSema combination is under FDA review, not yet approved — Novo Nordisk filed the combination NDA in late 2025 with a decision expected later in 2026, while the standalone program has no NDA on file.

That means any cagrilintide available to a consumer today is gray-market: sold “for research,” with no guarantee of what’s actually in the vial. So the real-world risk picture isn’t just the drug’s biology — it’s the drug’s biology applied to a product of unknown concentration and purity, self-administered without the monitoring that catches the rare-but-serious events early. A side-effect profile measured in a controlled trial does not transfer to an unverified vial used without supervision. If you’re weighing this compound, that distinction matters more than any percentage on this page. For what legitimate access does and doesn’t exist, see how to get cagrilintide.

How to read a cagrilintide side-effect claim

A quick filter for anything you encounter:

1. Monotherapy or CagriSema? If the source doesn’t say, treat the numbers as combination data — most of the big figures are.
2. Which trial and dose? GI rates are strongly dose-dependent; a 0.3 mg figure and a 4.5 mg figure are different worlds.
3. Trial-grade or gray-market context? A clean trial profile says nothing about an unverified vial.

Applied honestly, the bottom line is this: cagrilintide’s own side-effect profile looks like a typical amylin analog — GI-led, injection-site-prone, mostly mild and dose-dependent, possibly easier on nausea than a GLP-1. But the data most people quote is CagriSema’s two-drug profile, the standalone picture is less mature than for approved drugs, and none of it was generated under the conditions a self-experimenter would actually face. For the broader framework on reading peptide safety claims, see the peptide side effects fundamentals; for how cagrilintide’s profile compares with the GLP-1 it’s paired with, see semaglutide side effects.